2024 American Academy of Neurology Abstract Website

Disclosures for "Granulocyte Activation and Astrocyte Damage Markers in CSF Differentiate Acute NMOSD and MOGAD from MS"

Dr. Leppert has received personal compensation for serving as an employee of GeNeuro. Dr. Leppert has received personal compensation for serving as an employee of GeNeuro. Dr. Leppert has received personal compensation for serving as an employee of Geneuro. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Leppert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Leppert has received personal compensation in the range of $0-$499 for serving as a Consultant for Orion. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Leppert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quanterix. Dr. Leppert has stock in Novartis.
Dr. Watanabe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharma. Dr. Watanabe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Japan. Dr. Watanabe has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis Pharma. Dr. Watanabe has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen Japan. Dr. Watanabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma. Dr. Watanabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chugai Pharmaceutical. Dr. Watanabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Dr. Watanabe has received research support from JSPS KAKENHI.
Sabine Schaedelin has nothing to disclose.
Dr. Piehl has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parexel/Chugai. The institution of Dr. Piehl has received research support from UCB. The institution of Dr. Piehl has received research support from Merck KGaA. Dr. Piehl has received personal compensation in the range of $10,000-$49,999 for serving as a member scientific advisory board with Swedish Medical products Agency.
The institution of Dr. Fink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Fink has received personal compensation in the range of $0-$499 for serving as a Lecturer with Swedish MS Society.
Roberto Furlan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck, Novartis, Roche, Biogen, Genzyme.
Dr. Gastaldi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche.
Pascal Benkert has nothing to disclose.
Miss Maceski has nothing to disclose.
Dr. Willemse has nothing to disclose.
The institution of Dr. Oechtering has received research support from Swiss MS Society.
Dr. Orleth has nothing to disclose.
Miss Meier has nothing to disclose.
Dr. Anthony has received personal compensation for serving as an employee of University of Oxford. Dr. Anthony has received personal compensation for serving as an employee of Somerville College Oxford. Dr. Anthony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Anthony has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroplast. Dr. Anthony has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Oxomics. The institution of Dr. Anthony has received research support from Numares. The institution of Dr. Anthony has received research support from MRC UK.
Dr. Kuhle has nothing to disclose.